Lisowska, Katarzyna A <br/><br/>
Recombinant human erythropoietin treatment of chronic renal failure patients normalizes altered phenotype and proliferation of CD4-positive T lymphocytes.  [electronic resource] 

 -  Artificial organs  Mar 2010 
 - E77-84 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1525-1594 
<br/><br/><label>Standard No.: </label>10.1111/j.1525-1594.2009.00942.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, CD--metabolism<br/>Antigens, Differentiation, T-Lymphocyte--metabolism<br/>CD28 Antigens--metabolism<br/>CD4-Positive T-Lymphocytes--drug effects<br/>CD40 Ligand--metabolism<br/>Cell Proliferation--drug effects<br/>Cells, Cultured<br/>Epoetin Alfa<br/>Erythropoietin--therapeutic use<br/>Female<br/>Flow Cytometry<br/>Hematinics--therapeutic use<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Immunophenotyping--methods<br/>Kidney Failure, Chronic--blood<br/>Kinetics<br/>Lectins, C-Type--metabolism<br/>Lymphocyte Activation--drug effects<br/>Male<br/>Middle Aged<br/>Phenotype<br/>Recombinant Proteins<br/>Renal Dialysis<br/>Treatment Outcome